SPY756.34−0.46%QQQ683.79−0.95%BTC/USD72,796.00−1.53%DIA524.58+0.03%GLD360.89−1.17%TLT80.91−0.01%

Vir Biotechnology Inc

VIRNASDAQ

Trade with Public

$13.13

-0.02-0.15%

Last update: Nov 12, 7:08 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Vir Biotechnology (VIR) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Vir Biotechnology (VIR) stock.

Analyst Consensus — 9 Analysts

8Buy

1Hold

# Analysts9

Latest Upgrades and Downgrades for Vir Biotechnology Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Morgan Stanley	Michelle Gilson	PT Raise	Overweight	$25→$28
—	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$22→$25
—	Needham	Joseph Stringer	PT Raise	Buy	$20→$24
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$22
—	Needham	Joseph Stringer	PT Raise	Buy	$18→$20
—	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$20→$22
—	Morgan Stanley	Michelle Gilson	PT Raise	Overweight	$23→$27
—	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$20→$21
—	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$15→$20
—	Barclays	Etzer Darout	PT Raise	Overweight	$26→$30
—	Morgan Stanley	Michelle Gilson	PT Raise	Overweight	$20→$24
—	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$12→$18
—	Needham	Joseph Stringer	PT Raise	Buy	$14→$18
—	Needham	Joseph Stringer	Maintained	Buy	$14
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$15
—	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$15
—	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$12
—	B of A Securities	Geoff Meacham	Upgrade	Neutral→Buy	$12→$14
—	Raymond James	Sean McCutcheon	Initiate	Outperform	$12
—	Needham	Joseph Stringer	Maintained	Buy	$14

Vir Biotechnology Inc

Vir Biotechnology (VIR) Stock Price Target 2026

Latest Upgrades and Downgrades for Vir Biotechnology Stock

Vir Biotechnology (VIR) Stock Price Target 2026

Latest Upgrades and Downgrades for Vir Biotechnology Stock

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28

PRO
Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

PRO
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target

PRO
Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28

PRO
Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

PRO
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target

PRO
Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

Vir Biotechnology Inc

Vir Biotechnology (VIR) Stock Price Target 2026

Latest Upgrades and Downgrades for Vir Biotechnology Stock

Vir Biotechnology (VIR) Stock Price Target 2026

Latest Upgrades and Downgrades for Vir Biotechnology Stock

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28

PROEvercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

PROHC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target

PRONeedham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PROHC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

PROMorgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

People Also Watch

People Also Watch

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28

PROEvercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

PROHC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target

PRONeedham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PROHC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

PROMorgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28

PRO
Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

PRO
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target

PRO
Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28

PRO
Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25

PRO
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target

PRO
Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27